	Application No.	Applicant(s)
Nedles of Allematility	09/656,364	MARTINO ET AL.
Notice of Allowability	Examiner	Art Unit
	Shahnam Sharareh	1617
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>11/14/2005</u> .		
2. The allowed claim(s) is/are <u>2-20,22-24,26,34,36,70 and 71</u> .		
3. ☑ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☑ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	5 🖾 🖽 💮 🗘	
1. Notice of References Cited (PTO-892)		atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 Interview Summary (Paper No./Mail Date 	
 Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 	8), 7. 🛛 Examiner's Amendm	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Statement	nt of Reasons for Allowance
o. Diological Material	9.	

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sidney Williams on February 15, 2006.

The application has been amended as follows:

In all claims 2, 3, 4, 5, 6, 7, 9. 13, 17, 22, 24, 26, 36 change the dependency from claim 68 to claim 71.

The following is an examiner's statement of reasons for allowance: the prior art does not teach compositions of rapidly precipitating drug which is a salt form of a poorly soluble free base that is prone to super saturation when introduced in water or simulated fluid at body temperature, and more than 90% of it precipitates outwithin 60 min after coming to contact with said water or simulated physiological fluid, and the combination of said drug form with specific amounts of polymeric binder, a super disintegrant and a lubricant by a process wherein said ingredients are mixed and compressed without heating, solvent or grinding.

Applicant has also provided declarations for unexpected improved bioavailability of the dosage forms when the claimed specific concentrations of polymeric binder and superdisintegrants are mixed with the drug in a salt form of a poorly soluble free base

Application/Control Number: 09/656,364

Art Unit: 1617

by delaying precipitation of the drug from the supersaturated solution. (see Declarations filed by Martino on Jan 16, 2003 and July 11, 2003).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shahnam Sharareh whose telephone number is 571-272-0630. The examiner can normally be reached on 8:30 am - 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, PhD can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

OTETNI PADMANADI IAN OTETNI PATENT BALLININIAN ONE. . V. LOCKY PATENT EXCENTICA

Page 3

SS